www.finanznachrichten.de ·
68409193 livanova plc livanova reports first quarter 2026 results raises full year 2026 revenue and adjusted diluted eps guidance 004
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedLivaNova's strong Q1 results and raised guidance reflect robust demand for its neuromodulation and cardiac surgery products. The FDA approval of aura6000 expands its addressable market in obstructive sleep apnea, a large and growing condition. The company's margin expansion (from a loss to profit) indicates operational leverage. The impact is company-specific, but the medical device sector benefits from innovation and regulatory approvals.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- LivaNova Q1 2026 revenue $362.3M, +14.3% YoY
- Raised FY2026 revenue growth guidance to 7.0%-8.0%
- Raised FY2026 adjusted diluted EPS guidance to $4.20-$4.30
- FDA premarket approval for aura6000 System, first hypoglossal nerve stimulation device without contraindications for OSA
- Q1 2026 GAAP diluted EPS $0.40 vs -$6.01 in Q1 2025
LivaNova's aura6000 adoption supports flat revenue growth expectations in medical devices over the next 1-4 weeks.
Sign in to see all sector verdicts, full thesis and counter-argument debate.